SBFM
Sunshine Biopharma, Inc. [SBFM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SBFM Stock Summary
Top 10 Correlated ETFs
SBFM
Top 10 Correlated Stocks
SBFM
In the News
SBFM Financial details
Company Rating
Neutral
Market Cap
7.97M
Income
-4.51M
Revenue
24.09M
Book val./share
0.89
Cash/share
0.68
Dividend
-
Dividend %
-
Employees
44
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.24
Forward P/E
-
PEG
0.03
P/S
0.32
P/B
0.3
P/C
4.88
P/FCF
-0.74
Quick Ratio
4.1
Current Ratio
5
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
-0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-89.2%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-62.82%
Revenue last 5Y
308.73%
Revenue Q/Q
28.91%
EPS Q/Q
105.91%
-
-
-
-
SMA20
32.67%
SMA50
-70.32%
SMA100
-72.08%
Inst Own
0%
Inst Trans
0.87%
ROA
-97%
ROE
-124%
ROC
-0.38%
Gross Margin
36%
Oper. Margin
-42%
Profit Margin
-132%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.044-1.4
52W High
-
52W Low
-
RSI
34.85
Rel Volume
0.13
Avg Volume
23.22M
Volume
2.91M
Perf Week
-65.24%
Perf Month
-49.7%
Perf Quarter
-89.54%
Perf Half Y
-89.63%
-
-
-
-
Beta
-1.105
-
-
Volatility
2.26%, 2.04%
Prev Close
-12.63%
Price
3.32
Change
-7%
SBFM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.39 | 0.07 | 17.49 | 0.29 | 0.99 | |
| Net income per share | -26.73 | -0.88 | -977.43 | -1.76 | -0.19 | |
| Operating cash flow per share | -9.07 | -0.64 | -140.06 | -0.35 | -0.36 | |
| Free cash flow per share | -9.09 | -0.65 | -140.06 | -0.37 | -0.39 | |
| Cash per share | 0.88 | 0.98 | 157.18 | 1.44 | 0.67 | |
| Book value per share | -13.45 | -0.94 | 16.21 | 1.42 | 0.87 | |
| Tangible book value per share | -13.45 | -0.94 | 16.21 | 1.37 | 0.81 | |
| Share holders equity per share | -13.45 | -0.94 | 16.21 | 1.42 | 0.87 | |
| Interest debt per share | 15.21 | 2.04 | 170.66 | 0.28 | 0.03 | |
| Market cap | 24.6 | 16.02K | 763.36 | 9.72M | 6.61M | |
| Enterprise value | 675.09K | 939.25K | -144.4K | -7.84M | -9.03M | |
| P/E ratio | 0 | -0.02 | 0 | -0.36 | -1.47 | |
| Price to sales ratio | 0 | 0.22 | 0 | 2.24 | 0.27 | |
| POCF ratio | 0 | -0.02 | 0 | -1.85 | -0.75 | |
| PFCF ratio | 0 | -0.02 | 0 | -1.75 | -0.69 | |
| P/B Ratio | 0 | -0.02 | 0 | 0.45 | 0.31 | |
| PTB ratio | 0 | -0.02 | 0 | 0.45 | 0.31 | |
| EV to sales | 31.96 | 13.15 | -0.63 | -1.8 | -0.37 | |
| Enterprise value over EBITDA | -0.72 | -0.36 | 0.06 | 0.96 | 1.95 | |
| EV to operating cash flow | -1.36 | -1.43 | 0.08 | 1.49 | 1.03 | |
| EV to free cash flow | -1.36 | -1.43 | 0.08 | 1.41 | 0.94 | |
| Earnings yield | -59.41K | -56.03 | -16.72K | -2.75 | -0.68 | |
| Free cash flow yield | -20.19K | -41.1 | -2.4K | -0.57 | -1.45 | |
| Debt to equity | -0.97 | -2 | 8.98 | 0.2 | 0.03 | |
| Debt to assets | 7.29 | 1.83 | 0.86 | 0.15 | 0.02 | |
| Net debt to EBITDA | -0.72 | -0.35 | 0.06 | 2.16 | 3.37 | |
| Current ratio | 0.08 | 0.98 | 24.07 | 3.94 | 4.48 | |
| Interest coverage | -5.54 | -3.43 | -7.42 | -220.09 | -34.85 | |
| Income quality | 0.3 | 0.24 | 0.15 | 0.2 | 1.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 29.48 | 7.67 | 8.17 | 2.05 | 0.42 | |
| Research and developement to revenue | 0.72 | 0.85 | 2.94 | 0.19 | 0.08 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.03 | 0.05 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.06 | 0.09 | |
| Capex to revenue | -0.04 | -0.02 | 0 | -0.07 | -0.03 | |
| Capex to depreciation | -0.06 | -0.08 | 0 | -12.12 | -5.28 | |
| Stock based compensation to revenue | 12.39 | 0.7 | 4.02 | 0 | 0 | |
| Graham number | 89.96 | 4.3 | 597.01 | 7.51 | 1.91 | |
| ROIC | 43.89 | -0.19 | -1.19 | -0.33 | -0.23 | |
| Return on tangible assets | -14.89 | -0.86 | -5.79 | -0.94 | -0.17 | |
| Graham Net | -14.22 | -0.97 | 9.2 | 1.14 | 0.61 | |
| Working capital | -767.84K | -25.36K | 2.1M | 20.38M | 19.34M | |
| Tangible asset value | -735.39K | -954.84K | 211.66K | 20.85M | 19.76M | |
| Net current asset value | -767.84K | -974.37K | 204.6K | 19.7M | 18.75M | |
| Invested capital | -0.97 | -2 | 8.98 | 0.2 | 0.03 | |
| Average receivables | 47.69K | 1.17K | 4.86K | 959.98K | 2.23M | |
| Average payables | 143.98K | 79.88K | 52.91K | 1.42M | 2.69M | |
| Average inventory | 7.96K | 19.84K | 64.71K | 1.7M | 4.51M | |
| Days sales outstanding | 7.43 | 9.79 | 12.46 | 160.61 | 38.67 | |
| Days payables outstanding | 3.2K | 887.82 | 133.02 | 386.19 | 59.34 | |
| Days of inventory on hand | 525.53 | 335.68 | 327.27 | 453.31 | 131.62 | |
| Receivables turnover | 49.12 | 37.27 | 29.29 | 2.27 | 9.44 | |
| Payables turnover | 0.11 | 0.41 | 2.74 | 0.95 | 6.15 | |
| Inventory turnover | 0.69 | 1.09 | 1.12 | 0.81 | 2.77 | |
| ROE | 1.99 | 0.94 | -60.31 | -1.24 | -0.21 | |
| Capex per share | -0.02 | 0 | 0 | -0.02 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.17 | 0.22 | 0.22 | 0.23 | 0.32 | |
| Net income per share | -1.04 | -0.08 | -0.04 | -0.03 | -0.05 | |
| Operating cash flow per share | -0.1 | -0.08 | -0.15 | -0.02 | -0.11 | |
| Free cash flow per share | -0.11 | -0.09 | -0.16 | -0.02 | -0.13 | |
| Cash per share | 0.97 | 0.88 | 0.78 | 0.73 | 0.68 | |
| Book value per share | 0.96 | 0.88 | 0.91 | 0.85 | 0.89 | |
| Tangible book value per share | 0.92 | 0.84 | 0.86 | 0.81 | 0.89 | |
| Share holders equity per share | 0.96 | 0.88 | 0.91 | 0.85 | 0.89 | |
| Interest debt per share | 0.19 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Market cap | 14.45M | 16.11M | 12.55M | 8.22M | 6.49M | |
| Enterprise value | -3.1M | -2.45M | -6.46M | -9.95M | -9.15M | |
| P/E ratio | -0.15 | -2.37 | -3.48 | -3.15 | -1.3 | |
| Price to sales ratio | 3.67 | 3.29 | 2.26 | 1.38 | 0.84 | |
| POCF ratio | -6.43 | -8.71 | -3.32 | -17.98 | -2.41 | |
| PFCF ratio | -5.66 | -7.94 | -3.08 | -17.53 | -2.17 | |
| P/B Ratio | 0.67 | 0.83 | 0.54 | 0.37 | 0.31 | |
| PTB ratio | 0.67 | 0.83 | 0.54 | 0.37 | 0.31 | |
| EV to sales | -0.79 | -0.5 | -1.16 | -1.67 | -1.19 | |
| Enterprise value over EBITDA | 0.63 | 1.55 | 8.6 | 18.61 | 10.7 | |
| EV to operating cash flow | 1.38 | 1.32 | 1.71 | 21.76 | 3.4 | |
| EV to free cash flow | 1.21 | 1.21 | 1.59 | 21.22 | 3.06 | |
| Earnings yield | -1.63 | -0.11 | -0.07 | -0.08 | -0.19 | |
| Free cash flow yield | -0.18 | -0.13 | -0.32 | -0.06 | -0.46 | |
| Debt to equity | 0.2 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Debt to assets | 0.15 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Net debt to EBITDA | 3.58 | 11.74 | 25.29 | 33.98 | 18.28 | |
| Current ratio | 3.94 | 3.61 | 5.6 | 5 | 4.48 | |
| Interest coverage | -189.74 | -44.53 | -35.86 | -20.23 | -29.81 | |
| Income quality | 0.1 | 1.09 | 4.19 | 0.7 | 2.15 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | -0.04 | 0 | |
| Sales general and administrative to revenue | 1.58 | 0.61 | 0.42 | 0.37 | 0.34 | |
| Research and developement to revenue | 0.01 | 0.09 | 0.07 | 0.04 | 0.11 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Capex to operating cash flow | 0.14 | 0.1 | 0.08 | 0.03 | 0.11 | |
| Capex to revenue | -0.08 | -0.04 | -0.05 | 0 | -0.04 | |
| Capex to depreciation | -16.07 | -5.14 | -8.43 | -0.32 | -7.17 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.74 | 1.24 | 0.85 | 0.7 | 1.02 | |
| ROIC | -0.19 | -0.09 | -0.04 | -0.04 | -0.05 | |
| Return on tangible assets | -0.83 | -0.07 | -0.03 | -0.02 | -0.05 | |
| Graham Net | 0.77 | 0.68 | 0.71 | 0.66 | 0.63 | |
| Working capital | 20.38M | 18.04M | 21.44M | 20.35M | 19.34M | |
| Tangible asset value | 20.85M | 18.48M | 21.88M | 20.75M | 19.76M | |
| Net current asset value | 19.7M | 17.39M | 20.8M | 19.75M | 18.75M | |
| Invested capital | 0.2 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Average receivables | 956.09K | 1.85M | 1.9M | 2.02M | 2.29M | |
| Average payables | 1.64M | 2.77M | 2.25M | 1.99M | 2.4M | |
| Average inventory | 1.78M | 3.5M | 3.98M | 4.38M | 5.13M | |
| Days sales outstanding | 43.68 | 32.93 | 32.55 | 30.73 | 29.91 | |
| Days payables outstanding | 103.01 | 80.32 | 43.9 | 50.38 | 45.14 | |
| Days of inventory on hand | 120.92 | 108.91 | 106.03 | 102.47 | 100.13 | |
| Receivables turnover | 2.06 | 2.73 | 2.76 | 2.93 | 3.01 | |
| Payables turnover | 0.87 | 1.12 | 2.05 | 1.79 | 1.99 | |
| Inventory turnover | 0.74 | 0.83 | 0.85 | 0.88 | 0.9 | |
| ROE | -1.09 | -0.09 | -0.04 | -0.03 | -0.06 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | -0.01 |
SBFM Frequently Asked Questions
What is Sunshine Biopharma, Inc. stock symbol ?
Sunshine Biopharma, Inc. is a CA stock , located in Pointe-claire of Qc and trading under the symbol SBFM
What is Sunshine Biopharma, Inc. stock quote today ?
Sunshine Biopharma, Inc. stock price is $3.32 today.
Is Sunshine Biopharma, Inc. stock public?
Yes, Sunshine Biopharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 23.22M
- Market Capitalization 7.97M
- Employee 44
- CEO Dr. Steve N. Slilaty Ph.D.
- Headquarters Pointe-Claire,QC,CA
- IPO Date 2022-02-15
-
Website
https://www.sunshinebiopharma.com 
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
